DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused on dermatological treatments. DUSA markets and continues to develop its Levulan Photodynamic Therapy (PDT) technology platform, which is a treatment for the pre-cancerous skin lesions known as Actinic Keratoses (AK). DUSA is also developing certain internal indications of Levulan PDT. DUSA's portfolio of complementary dermatology products includes ClindaReach, which was acquired from Sirius Laboratories, Inc. ClindaReach is a topical acne treatment which includes a novel applicator for hard-to-reach areas.
CSRHub includes data on ESG ratings, Sustainable Accounting Standards Board, workplace, mutual funds investment, Environment, and real estate investing.